keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis B antiviral therapy

keyword
https://www.readbyqxmd.com/read/28323868/-waiting-for-daas-a-retrospective-chart-review-of-patients-with-untreated-hepatitis-c-in-rwanda
#1
Neil Gupta, Jules Kabahizi, Constance Mukabatsinda, Timothy David Walker, Emmanuel Musabeyezu, Athanase Kiromera, Jennifer Ilo Van Nuil, Kevin Steiner, Joia Mukherjee, Sabin Nsanzimana, Aimable Mbituyumuremyi
BACKGROUND: Access to treatment for hepatitis C virus (HCV) in sub-Saharan Africa is extremely limited. With the advent of direct acting antivirals (DAAs), highly effective and easy-to-deliver oral regimens are now available on the global market. This study was conducted to understand the background and characteristics of a national cohort of patients with HCV infection enrolled in care and awaiting therapy with DAAs. METHODS AND FINDINGS: We conducted a retrospective chart review of all adult patients with confirmed HCV infection who were currently enrolled in care and treatment at the four existing hepatitis referral centers in Rwanda...
2017: PloS One
https://www.readbyqxmd.com/read/28323748/serum-aminotransferase-flares-in-pregnant-and-postpartum-women-with-current-or-prior-treatment-for-chronic-hepatitis-b
#2
Christine Y Chang, Natali Aziz, Mugilan Poongkunran, Asad Javaid, Huy N Trinh, Daryl T Lau, Mindie H Nguyen
BACKGROUND AND AIMS: Antiviral therapy is recommended for pregnant women with chronic hepatitis B (CHB) and hepatitis B virus (HBV) DNA>200,000 IU/mL, but there is less consensus on management of women who discontinue therapy in anticipation of pregnancy or who become pregnant while on therapy. The goal of this study was to describe flares in alanine aminotransferase (ALT) during pregnancy and postpartum in CHB women with current and/or prior treatment. METHODS: This was a multicenter, retrospective study of 67 pregnancies in 56 CHB women treated before and/or during pregnancy...
March 20, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28319996/oral-direct-acting-agent-therapy-for-hepatitis-c-virus-infection-a-systematic-review
#3
Oluwaseun Falade-Nwulia, Catalina Suarez-Cuervo, David R Nelson, Michael W Fried, Jodi B Segal, Mark S Sulkowski
Background: Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acting antiviral (DAA) regimens by the U.S. Food and Drug Administration (FDA) for treatment of chronic HCV infection. Purpose: To summarize published literature on the efficacy and safety of oral DAAs for treatment of persons with chronic HCV infection. Data Sources: MEDLINE and EMBASE from inception through 1 November 2016. Study Selection: 42 English-language studies from controlled and single-group registered clinical trials of adults with HCV infection that evaluated at least 8 weeks of an FDA-approved interferon-free HCV regimen that included at least 2 DAAs...
March 21, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28300730/the-enrichment-of-hbv-immune-escape-mutations-during-nucleoside-nucleotide-analogue-therapy
#4
Menglin Shan, Zhen Shen, Hua Sun, Jianghua Zheng, Min Zhang
BACKGROUND: Drug-resistant HBV mutants frequently arise during nucleos(t)ide analogues (NAs) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. Besides, the enrichment of immune-escape mutations was negatively correlated with HBsAg clearance under NAs therapy. This study aims to characterize the variability of hepatitis B virus polymerase and surface antigen in patients with virologic breakthrough under nucleos(t)ide analogues therapy...
March 16, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28297788/-advances-in-clinical-research-on-rta181-mutation-in-hepatitis-b-virus
#5
X L Gong, R Liu, Y X Liu, Y Zhang
Nowadays, nucleos(t)ide analogues (NAs) are important drugs for the treatment of chronic hepatitis B and can suppress the virus through inhibiting the activity of hepatitis B virus (HBV) polymerase. However, rtA181 mutation in HBV can reduce the sensitivity of HBV to various NAs, which brings new challenges to antiviral therapy. This article briefly introduces the research advances in the clinical detection rate of rtA181 mutation and its influence on therapeutic effect and prognosis.
January 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/28295463/immune-phenotype-and-function-of-nk-and-t-cells-in-chronic-hepatitis-c-patients-who-received-a-single-dose-of-anti-mir-122-rg-101
#6
Femke Stelma, Meike H van der Ree, Marjan J Sinnige, Anthony Brown, Leo Swadling, J Marleen L de Vree, Sophie B Willemse, Marc van der Valk, Paul Grint, Steven Neben, Paul Klenerman, Eleanor Barnes, Neeltje A Kootstra, Hendrik W Reesink
MicroRNA-122 (miR-122) is an important host factor for the hepatitis C (HCV) virus. Treatment with RG-101, a GalNAc conjugated anti-miR-122 oligonucleotide, resulted in a significant viral load reduction in patients with chronic hepatitis C (CHC) infection. Here, we analyzed the effects of RG-101 therapy on antiviral immunity. 32 CHC patients HCV genotype 1, 3 and 4 received a single subcutaneous administration with RG-101 at 2 mg/kg (n=14), 4 mg/kg (n=14) or placebo (n=2 per dosing group). Plasma and PBMCs were collected at multiple time points and comprehensive immunological analyses were performed...
March 11, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28292309/elimination-of-hepatitis-b-is-it-a-mission-possible
#7
REVIEW
Tai-Chung Tseng, Jia-Horng Kao
Chronic hepatitis B virus (HBV) infection is a global public health issue. Although the disease cannot be cured effectively, disease management has been improved over the past decade. The introduction of potent nucleos(t)ide analogues (NAs) to suppress viral replication represented a giant leap in the control of this disease. It has been shown that tenofovir treatment, a potent NA, complements current immunoprophylaxis to diminish mother-to-infant transmission in pregnant women with a high viral load. For patients with chronic HBV infection, quantitative hepatitis B surface antigen is a useful tool to define inactive carriers and to guide antiviral therapy...
March 15, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28288791/efficacy-and-safety-of-sofosbuvir-plus-daclatasvir-for-treatment-of-hcv-associated-cryoglobulinemia-vasculitis
#8
David Saadoun, Stanislas Pol, Yasmina Ferfar, Laurent Alric, Christophe Hezode, Si Nafa Si Ahmed, Luc de Saint Martin, Cloé Comarmond, Anne Sophie Bouyer, Lucile Musset, Thierry Poynard, Matthieu Resche Rigon, Patrice Cacoub
Circulating mixed cryoglobulins are detected in 40%-60% of patients with hepatitis C virus (HCV) infection, and overt cryoglobulinemia vasculitis (CryoVas) develops in about 15% of patients. Remission of vasculitis has been associated with viral clearance, but few studies have reported the effectiveness of direct acting antiviral drugs in these patients. We performed open-label, prospective, multi-center study of the effectiveness and tolerance of an all-oral, interferon- and ribavirin-free regimen of sofosbuvir plus daclatasvir in patients with HCV-associated CryoVas...
March 10, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28288715/hepatitis-c-virus-associated-marginal-zone-lymphoma
#9
REVIEW
Marine Armand, Caroline Besson, Olivier Hermine, Frédéric Davi
The link between hepatitis C virus (HCV) infection and the development of B-cell non-Hodgkin lymphoma is now well established and based on a number of epidemiological studies. It is further supported by the observation of lymphoma regression after HCV eradication by antiviral treatment. The far most frequent entities are marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL). MZL usually emerge on a background of mixed cryoglobulinemia, a low-grade lymphoproliferation, and often transform into DLBCL, thereby following a multistep oncogenesis process...
March 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/28279168/comparison-of-the-long-term-efficacy-between-entecavir-and-tenofovir-in-treatment-na%C3%A3-ve-chronic-hepatitis-b-patients
#10
COMPARATIVE STUDY
Ji Won Park, Kyeong Min Kwak, Sung Eun Kim, Myoung Kuk Jang, Ki Tae Suk, Dong Joon Kim, Sang Hoon Park, Myung Seok Lee, Hyoung Su Kim, Choong Kee Park
BACKGROUND: There have been limited studies directly comparing the long-term efficacy between entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study was aimed to compare the long-term efficacy between them in treatment-naïve chronic hepatitis B (CHB). METHODS: Out of 345 CHB patients who received first line therapy with ETV (n = 200) or TDF (n = 145) in a cohort, 210 patients were analyzed using propensity score matching, at a ratio of 1:1...
March 9, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28274850/direct-acting-antiviral-therapy-restores-immune-tolerance-to-patients-with-hepatitis-c-virus-induced-cryoglobulinemia-vasculitis
#11
Cloé Comarmond, Marlène Garrido, Stanislas Pol, Anne-Claire Desbois, Myrto Costopoulos, Magali Le Garff-Tavernier, Si Nafa Si Ahmed, Laurent Alric, Hélène Fontaine, Bertrand Bellier, Anna Maciejewski, Michelle Rosenzwajg, David Klatzmann, Lucile Musset, Thierry Poynard, Patrice Cacoub, David Saadoun
BACKGROUND & AIMS: Interferon-free direct-acting antiviral (DAA) therapies are effective in patients with hepatitis C virus-induced cryoglobulinemia vasculitis (HCV-CV). We analyzed blood samples from patients with HCV-CV before and after DAA therapy to determine mechanisms of these drugs and their effects on cellular immunity. METHODS: We performed a prospective study of 27 consecutive patients with HCV-CV (median age 59 years) treated with DAA therapy (21 patients received sofosbuvir plus ribavirin for 24 weeks, 4 patients received sofosbuvir plus daclatasvir for 12 weeks, and 2 patients received sofosbuvir plus simeprevir for 12 weeks) in Paris, France...
March 5, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28274240/effect-of-48-week-pegylated-interferon-%C3%AE-2a-or-nucleos-t-ide-analogue-therapy-on-renal-function-in-chinese-patients-with-chronic-hepatitis-b
#12
Ye Zhang, Wei-Lu Zhang, Xiao-Wen Pang, Lin-Xu Wang, Xin Wei, Chang-Xing Huang, Xue-Fan Bai, Shuai Han, Lin-Na Liu, Jian-Qi Lian
BACKGROUND: Controversy remains as to whether antiviral agents contribute to renal dysfunction in patients with chronic hepatitis B virus (HBV) infection. Thus, the aim of study was to analyze the changes in renal function of chronic hepatitis B (CHB) patients in response to anti-HBV therapy and the association with treatments. METHOD: We performed a retrospective observational cohort study to investigate factors associated with renal function in 249 Chinese CHB patients who were treated with pegylated interferon α-2a (PEG-IFN-α-2a) or nucleos(t)ide analogues for 48 weeks...
March 9, 2017: Virology Journal
https://www.readbyqxmd.com/read/28273387/long-term-trends-in-chronic-hepatitis-b-virus-infection-associated-liver-transplantation-outcomes-in-the-united-states
#13
Kellie Young, Benny Liu, Taft Bhuket, Zobair Younossi, Sammy Saab, Aijaz Ahmed, Robert J Wong
With effective antiviral therapies, rates of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and decompensated liver disease requiring liver transplantation (LT) are expected to decrease. We aim to evaluate overall trends in LT waitlist registrations, waitlist survival, and likelihood of receiving LT among chronic HBV patients in the U.S. Using the United Network for Organ Sharing database, we retrospectively evaluated adults (age >18) with chronic HBV (with and without HCC) listed for LT from 1992-1996 (Era 1) vs...
March 8, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28273209/influence-of-treg-cells-and-hbv-genotype-on-sustained-response-and-drug-resistance-in-the-treatment-with-nucleoside-drugs
#14
Y R Zhang, B Li, C X Wang, N Zhou, W Qi, X L Li, L Y Wu, S F Wei, Y D Zhang
We aimed to investigate the influence of regulatory T cells including CD4+CD25+, CD8+CD28- and hepatitis B virus (HBV) genotype on sustained virological response and tolerance of nucleoside drugs. One hundred and thirty-seven patients were enrolled. Lamivudine was administered to 84 patients. Entecavir was administered to the other 53 patients. Before treatment, biochemical tests, HBV DNA load, HBV serum level, HBV genotype, PB CD3+, CD4+, CD8+, CD4+CD25+/CD3+, and CD8+CD28-/CD3+ frequencies were measured. Based on HBV DNA loads after 4 weeks of therapy, patients were divided into response group and suboptimal response group...
March 2, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/28272219/predictive-value-of-serum-alt-and-t-cell-receptor-beta-variable-chain-for-hbeag-seroconversion-in-chronic-hepatitis-b-patients-during-tenofovir-treatment
#15
Jiezuan Yang, Dong Yan, Renyong Guo, Jiajia Chen, Yongtao Li, Jun Fan, Xuyan Fu, Xinsheng Yao, Hongyan Diao, Lanjuan Li
Effective antiviral therapy plays a key role in slowing the progression of chronic hepatitis B (CHB). Identification of serum indices, including hepatitis B e antigen (HBeAg) expression and seroconversion, will facilitate evaluation of the efficacy of antiviral therapy in HBeAg-positive CHB patients. The biochemical, serological, virological parameters, and the frequency of circulating CD4CD25 regulatory T cell (Treg) in 32 patients were measured at baseline and every 12 weeks during 96 weeks of tenofovir disoproxil fumarate (TDF) treatment...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28270871/antiviral-therapy-in-chronic-hepatitis-b-with-mild-acute-exacerbation
#16
Su Lin, Qiaoxia Ye, Mingfang Wang, Yinlian Wu, Zhiyuan Weng, Yueyong Zhu
BACKGROUND: The aim of this study was to assess the efficacy and safety of peginterferon α-2a (pegIFN) and nucleos(t)ide analogues (NA) treatments in patients with hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B (CHB) with mild acute exacerbation (AE). METHODS: Treatment-naive HBeAg-positive CHB patients with AE who received pegIFN or NA (entecavir (ETV) or telbivudine (LDT)) therapies were retrospectively selected. The HBeAg seroconversion rate, hepatitis B surface antigen (HBsAg) loss rate and the cost-effectiveness of different treatments were compared...
February 2017: Gastroenterology Research
https://www.readbyqxmd.com/read/28268819/a-comparison-of-multimodal-biomarkers-for-chronic-hepatitis-b-assessment-using-recursive-feature-elimination
#17
Yanru Bai, Xin Chen, Changfeng Dong, Yingxia Liu, Zhiguo Zhang
An effective assessment of liver fibrosis in patients with chronic hepatitis B (CHB) is highly desired because it is important not only for clinical courses prediction, but also for the determination of antiviral therapy schemes. In recent years, various approaches for liver biopsies analysis have been highlighted, such as elastography techniques and serum markers, due to their properties of non-invasiveness. The aim of this study is to determine the best biomarkers or their combination by comparing multimodal biomarkers (ultrasound elastography parameters, biochemical hematologic parameters, and clinical parameters) for fibrosis assessment in chronic hepatitis B using a support vector machine combined with recursive feature elimination (RFE-SVM) approach...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28267900/augmentation-of-hcv-specific-immunity-and-sustained-virological-response-svr
#18
Shikha Shrivastava, E Wilson, B Poonia, L Tang, A Osinusi, A Kohli, Shyam Kottilil
BACKGROUND: Treatment for chronic hepatitis C virus (HCV) infection has rapidly evolved into interferon-free directly acting antiviral regimens (DAA) that result in high sustained-virologic-response. DAAs primarily work by suppressing HCV replication and rely less on the immune system than interferon-based therapies. However it is unclear whether the immune system recovers with suppression of HCV replication and contributes to HCV clearance with DAA therapy. We previously demonstrated HCV clearance is associated with increased HCV-specific-immunity in CHCV-GT-1 infected patients during treatment with sofosbuvir (SOF)+ribavirin (RBV)...
March 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28266989/reply-to-letter-adjuvant-antiviral-therapy-with-nucleos-t-ide-analogs-in-patients-with-hepatitis-b-virus-related-hepatocellular-carcinoma
#19
Lei Yin, Gang Huang, Wan Yee Lau, Wei Ping Zhou
No abstract text is available yet for this article.
April 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28266988/postoperative-antiviral-therapy-with-nucleos-t-ide-analogs-in-patients-with-hepatitis-b-virus-related-hepatocellular-carcinoma
#20
Jian-Hong Zhong, Liang Ma, Le-Qun Li
No abstract text is available yet for this article.
April 2017: Annals of Surgery
keyword
keyword
32508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"